BioInsights - Development of a scalable AAV production process in suspension cells

Development of a scalable AAV production process in suspension cells

Cell & Gene Therapy Insights 2021; 7(9), 1337

10.18609/cgti.2021.176

Published: 11 November 2021
FastFacts
Ann-Christin Magnusson

Watch the video or read the poster to learn about:

  • Optimization of AAV2 triple plasmid transfection using design of experiment (DoE)
  • An optimized transient transfection protocol that can be used for several different AAV serotypes to achieve high titers 
  • Scale up of production using XDR-10 and the ReadyToProcess WAVE™ 25 bioreactor systems

Ann-Christin holds a degree in Biomedical Engineering from Uppsala University, Sweden and has over 30 years of hands-on experience in cell culture of different cell lines. In her previous function, Ann-Christin developed different stable CHO cell lines from DNA construction to a final cell line for GMP production of recombinant protein. Ann-Christin joined Cytiva in 2008, and currently leads the upstream teams for cell culture, development of solutions for virus production for vaccine manufacturing and gene therapy applications.